Autopsy report · NCT03205891
Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas
Cause of deathStaffing, sites or logistics, also funding or business
“Change in treatment priorities for these disease types as well as staffing concerns.”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 1
- Sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Conditions
- Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic; Classical Hodgkin Lymphoma; Anaplastic Large Cell Lymphoma; CD30+ Peripheral T-cell Lymphoma
- Interventions
- Brentuximab Vedotin; TAK228; Glucose Monitor
- Participants
- 0
Trials that died the same way
- Modular Prevention Bundle for Non-ventilator-associated Hospital-acquired Pneumonia (nvHAP)
“COVID-Epidemic with changes in patient mix, restructuring of wards/departments, new standard-precautions” - Serratus Plane Block for Postoperative Pain Control
“We decided to terminate this study due to staffing changes and other limitations posed by the COVID-19 pandemic.” - Open Ended Trocar vs. Fenestrated Blunt Trocar in Bone Marrow Aspirate for Osteoarthritis
“COVID limitations and staff changes” - Temperature Manipulating Gloves for the Treatment of Insomnia
“Change in staffing and budget due to Covid-19” - A Study Comparing the Safety and Effectiveness of Cartilage Cell Injected Into the Lumbar Disc as Compared to a Placebo
“Change in clinical strategy”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.